Using a combination of transcriptomics, cytometry, and functional assays, we performed a detailed analysis of the phenotype and function of residual and recurrent CD8+ T cells following alefacept therapy in RO T1D subjects. Here, CD8A is linked to type 1 diabetes mellitus.